Last reviewed · How we verify
Anti-CD20 Targeting agent (anti-cd20-targeting-agent)
Days 1,8,15, and 22 of the first 28-day cycle and then on Day 1 of subsequent 21-day cycles. The ant
Anti-CD20 Targeting agent is a monoclonal antibody that binds to CD20 protein found on B cells, leading to their destruction. It is approved for treating B-cell malignancies and certain autoimmune conditions where B cells play a pathogenic role. This mechanism allows for selective depletion of abnormal or overactive B cells while preserving other immune functions.
At a glance
| Generic name | anti-cd20-targeting-agent |
|---|---|
| Sponsor | Pfizer Inc. |
| Drug class | Days 1,8,15, and 22 of the first 28-day cycle and then on Day 1 of subsequent 21-day cycles. The ant |
| Therapeutic area | Oncology |
| Phase | discontinued |
Mechanism of action
Anti-CD20 Targeting agent works by recognizing and binding to CD20, a protein marker found on the surface of B cells. B cells are white blood cells that play important roles in both normal immunity and in certain diseases. By targeting CD20, this drug can selectively identify and eliminate B cells that are causing disease. Once the drug binds to CD20 on B cells, it triggers several mechanisms of cell destruction. The immune system recognizes these marked cells as targets and destroys them through various pathways. Additionally, the drug can cause B cells to undergo programmed cell death directly. This results in a significant reduction in the number of B cells circulating in the body and in affected tissues. This selective B cell depletion is beneficial in conditions where B cells are either malignant (cancerous) or are mistakenly attacking the body's own tissues. By removing these problematic cells, the drug can shrink tumors, reduce cancer progression, or suppress harmful autoimmune responses. The effect is temporary, and B cells gradually repopulate over time, which is why patients typically require repeated treatments to maintain clinical benefit.
Approved indications
Pipeline indications
- Lymphoma — discontinued
Common side effects
Key clinical trials
- A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab (discontinued)
- A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid Tumor (discontinued)
- A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When (discontinued)
- Efficacy of Venetoclax in Combination With Rituximab in Waldenström's Macroglobulinemia (discontinued)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Anti-CD20 Targeting agent CI brief — competitive landscape report
- Anti-CD20 Targeting agent updates RSS · CI watch RSS
- Pfizer Inc. portfolio CI